Media Contact: Lissa Pavluk media@apellis.com (617) 977-6764
- July 24, 2023 Apellis Pharmaceuticals to Host Conference Call on July 31, 2023, to Discuss Second Quarter 2023 Financial Results
- July 10, 2023 Apellis Announces Seven Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting
- July 6, 2023 Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- June 7, 2023 Apellis Pharmaceuticals to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
- June 6, 2023 Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- May 25, 2023 Apellis Reports Top-Line Results from Phase 2 MERIDIAN Study in ALS
- May 5, 2023 Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- May 4, 2023 Apellis Pharmaceuticals Reports First Quarter 2023 Financial Results
- May 3, 2023 Apellis Pharmaceuticals to Present at the Bank of America Securities 2023 Healthcare Conference
- April 27, 2023 Apellis Pharmaceuticals to Host Conference Call on May 4, 2023, to Discuss First Quarter 2023 Financial Results
Displaying 11 - 20 of 250